477 related articles for article (PubMed ID: 23633335)
21. Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin.
De Schryver EL; Algra A; Kappelle LJ; van Gijn J; Koudstaal PJ
Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD001342. PubMed ID: 22972051
[TBL] [Abstract][Full Text] [Related]
22. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
De Schryver EL; Algra A; van Gijn J
Cochrane Database Syst Rev; 2007 Jul; (3):CD001820. PubMed ID: 17636684
[TBL] [Abstract][Full Text] [Related]
23. Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin.
Kamal AK; Naqvi I; Husain MR; Khealani BA
Cochrane Database Syst Rev; 2011 Jan; 2011(1):CD008076. PubMed ID: 21249700
[TBL] [Abstract][Full Text] [Related]
24. Antiplatelet agents for intermittent claudication.
Wong PF; Chong LY; Mikhailidis DP; Robless P; Stansby G
Cochrane Database Syst Rev; 2011 Nov; (11):CD001272. PubMed ID: 22071801
[TBL] [Abstract][Full Text] [Related]
25. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
26. Triflusal for preventing serious vascular events in people at high risk.
Costa J; Ferro JM; Matias-Guiu J; Alvarez-Sabin J; Torres F
Cochrane Database Syst Rev; 2005 Jul; (3):CD004296. PubMed ID: 16034926
[TBL] [Abstract][Full Text] [Related]
27. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin.
Algra A; De Schryver EL; van Gijn J; Kappelle LJ; Koudstaal PJ
Cochrane Database Syst Rev; 2006 Jul; (3):CD001342. PubMed ID: 16855967
[TBL] [Abstract][Full Text] [Related]
28. Anticoagulation for people with cancer and central venous catheters.
Akl EA; Ramly EP; Kahale LA; Yosuico VE; Barba M; Sperati F; Cook D; Schünemann H
Cochrane Database Syst Rev; 2014 Oct; (10):CD006468. PubMed ID: 25318061
[TBL] [Abstract][Full Text] [Related]
29. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
De Schryver EL; Algra A; van Gijn J
Cochrane Database Syst Rev; 2006 Apr; (2):CD001820. PubMed ID: 16625549
[TBL] [Abstract][Full Text] [Related]
30. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
Landolfi R; Di Gennaro L; Novarese L; Patrono C
Semin Thromb Hemost; 2006 Apr; 32(3):251-9. PubMed ID: 16673279
[TBL] [Abstract][Full Text] [Related]
31. Pre-operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding.
Tan YH; Lethaby A
Cochrane Database Syst Rev; 2013 Nov; (11):CD010241. PubMed ID: 24234875
[TBL] [Abstract][Full Text] [Related]
32. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
[TBL] [Abstract][Full Text] [Related]
33. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
34. Antiplatelet and anticoagulation for patients with prosthetic heart valves.
Little SH; Massel DR
Cochrane Database Syst Rev; 2003; (4):CD003464. PubMed ID: 14583979
[TBL] [Abstract][Full Text] [Related]
35. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.
Elliott MA; Tefferi A
Br J Haematol; 2005 Feb; 128(3):275-90. PubMed ID: 15667529
[TBL] [Abstract][Full Text] [Related]
36. Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials.
Mazza GL; Mead-Harvey C; Mascarenhas J; Yacoub A; Kosiorek HE; Hoffman R; Dueck AC; Mesa RA;
Lancet Haematol; 2022 Jan; 9(1):e38-e48. PubMed ID: 34971581
[TBL] [Abstract][Full Text] [Related]
37. Statins for acute ischemic stroke.
Squizzato A; Romualdi E; Dentali F; Ageno W
Cochrane Database Syst Rev; 2011 Aug; (8):CD007551. PubMed ID: 21833959
[TBL] [Abstract][Full Text] [Related]
38. Anticoagulants versus antiplatelet agents for acute ischaemic stroke.
Berge E; Sandercock P
Cochrane Database Syst Rev; 2002; (4):CD003242. PubMed ID: 12519590
[TBL] [Abstract][Full Text] [Related]
39. Parenteral anticoagulation in ambulatory patients with cancer.
Akl EA; Kahale LA; Ballout RA; Barba M; Yosuico VE; van Doormaal FF; Middeldorp S; Bryant A; Schünemann H
Cochrane Database Syst Rev; 2014 Dec; (12):CD006652. PubMed ID: 25491949
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
